Caroline Simons is a Litigation associate located in the Boston office and a member of the firm's Complex Commercial Litigation practice. Prior to joining the Complex Commercial Litigation group, she was a member of the firm's Patent Litigation practice in the New York office. Ms. Simons has worked on patent, complex commercial, and compliance matters for numerous clients, including Biogen, Medicis, Micron Technology, Sotheby's, and Lehman. Ms. Simons also has experience in a range of pro bono matters, including drafting an amicus brief for the U.S. Supreme Court and representing clients in asylum and child support matters.
Ms. Simons received her J.D. degree from Columbia Law School, where she served as Head Notes Editor for the Journal of Transnational Law, and her A.B. from Harvard University in Government.
Representative Experience
- Biogen Idec. v. Pfizer, Novartis, Serono and Bayer – Member of litigation team for plaintiff Biogen in patent infringement action in D.N.J. involving recombinant beta interferon treatment for multiple sclerosis as well as Massachusetts state law contract and arbitration issues
- Impax v. Medicis – Member of litigation team for defendant Medicis in contract dispute in Arizona state court
- Medicis v. Teva and Lupin; Medicis v. Mylan and Ranbaxy – Member of litigation team for plaintiff Medicis in patent infringement action in D. Maryland and D. Delaware involving antibiotic therapy for acne
- Rambus v. Micron – Member of litigation and appellate team for defendant and appellee Micron in patent infringement action and appeal to the U.S. Court of Appeals for the Federal Circuit
- Minor v. Sotheby's – Member of appellate team for plaintiff and appellee Sotheby's in appeal to the U.S. Court of Appeals for the Second Circuit
- In re Lehman Brothers Holdings, Inc., et al. – Member of litigation team in various adversary proceedings involving foreign exchange derivatives transactions
- Pepper v. United States – Member of appellate team for amicus appointed by the U.S. Supreme Court to defend judgment below involving proper application of the Federal Sentencing Guidelines post-Booker